Resource Logo

Continuous infusion (CI) bleomycin in AIDS-related Kaposi's sarcoma (KS) (Meeting abstract).


Proc Annu Meet Am Assoc Cancer Res; 34:A1118 1993. Unique Identifier :

Bleomycin is an active drug in KS, is cell-cycle phase-specific, and has a short terminal half-life, characteristics which make it suitable for CI. We administered 20 mg/m2/day as a 24-hr CI for 3 days to 17 patients (pts) with AIDS-related KS. All pts had biopsy-proven KS and measurable disease. Nine pts (53%) had bronchoscopically proven KS, and only 2 pts had received prior cytotoxic chemotherapy. A total of 53 cycles were administered. Toxicity was limited. There were 12 episodes of grade 3 and 1 episode of grade 4 neutropenia, no significant thrombocytopenia, and no episodes of febrile neutropenia. There were 5 infectious complications including a life-threatening episode of Clostridium septicemia. Of the first 15 pts treated, 5 partial remissions (33%) were observed using ECOG criteria and 8 pts (53%) responded by ACTG criteria (JCO 7:1201, 1989). Bleomycin by CI is active in pts with advanced AIDS-related KS with modest myelosuppression.

Acquired Immunodeficiency Syndrome/*DRUG THERAPY Bleomycin/*ADMINISTRATION & DOSAGE/ADVERSE EFFECTS Drug Administration Schedule Female Human Infusions, Intravenous Male Sarcoma, Kaposi's/*DRUG THERAPY Skin Neoplasms/*DRUG THERAPY ABSTRACT


Information in this article was accurate in July 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.